Year: 2021
Type: article
Abstract: Epitranscriptomics is an exciting emerging area that studies biochemical modifications of RNA. The field has been opened up by the technical efforts of the last decade to characterize and quantify RNA modifications, and this has led to a map of post-transcriptional RNA marks in normal cell fate and development. However, the scientific interest has been fuelled by the discovery of aberrant epitranscriptomes associated with human diseases, mainly cancer. The challenge is now to see whether epitrancriptomics offers mechanisms that can be effectively targeted by low MW compounds and are thus druggable. In this review, we will describe the principal RNA modifications (with a focus on mRNA), summarize the latest scientific evidence of their dysregulation in cancer and provide an overview of the state-of-the-art drug discovery to target the epitranscriptome. Finally, we will discuss the principal challenges in the field of chemical biology and drug development to increase the potential of targeted-RNA for clinical benefit. LINKED ARTICLES: This article is part of a themed issue on New avenues in cancer prevention and treatment (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.12/issuetoc.
Source: British Journal of Pharmacology
DOI: 10.1111/bph.15604
Authors: María Berdasco, Manel Esteller
Language: English
Topic: RNA modifications and cancer
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Awards: G166240035, G1973013009, G2094719262, G6088724463, G6298273575, G6399147440, Células parietales de la cápsula de Bowman (PECs), regeneración y daño en el trasplante renal. Identificación de dianas terapéuticas y terapia celular con PECs en isquemia-reperfusión, BLOQUEO DEL SRAA EN PACIENTES TRASPLANTADOS RENALES CON PRESENCIA DE PECs EN ORINA: ENSAYO CLÍNICO ALEATORIZADO DE VALSARTAN VERSUS PLACEBO, G7609399765
OpenAlex ID: W3175882847